Open AccessCan cyclin-dependent kinase 4/6 inhibitors convert inoperable breast cancer relapse to operability? A case report
Author(s) -
Michela Palleschi,
Roberta Maltoni,
Eleonora Barzotti,
Elisabetta Melegari,
Annalisa Curcio,
Lorenzo Cecconetto,
Samanta Sarti,
Silvia Manunta,
Andrea Rocca
Publication year - 2020
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v8.i3.517
Subject(s) - medicine , palbociclib , breast cancer , epirubicin , dysgeusia , cancer , radiation therapy , surgery , oncology , radiology , metastatic breast cancer , adverse effect
Pathological complete response (pCR) is rare in hormone receptor-positive (HR+) HER2-negative breast cancer (BC) treated with either endocrine therapy (ET) or chemotherapy. Radical resection of locoregional relapse, although potentially curative in some cases, is challenging when the tumor invades critical structures. The oral cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with ET has obtained a significant increase in objective response rates and progression-free survival in patients with advanced BC and is now being evaluated in the neoadjuvant setting. We present a clinical case of a patient with an inoperable locoregional relapse of HR+ HER2-negative BC who experienced pCR after treatment with palbociclib.